The list of warnings associated with the class of medications commonly used to treat rheumatoid arthritis and other ailments continue to increase. Today the FDA announced that the labels for the popular arthritis drugs Remicade, Humira, Cimzia, Simponi, and Embrel will now carry a boxed warning to highlight an increased risk of cancer in children and adolescents that take these medications.
In addition, the FDA is working with manufacturers to explore new ways to further define the risk of cancer in children and adolescents who use these drugs.
The action the FDA took today is based on the completion of data that was first announced by the administration last June. Analysis of the data showed an increased risk of cancer in children and adolescents after about 30 months of treatment. Roughly half of the cancers were lymphomas and some reported cases of cancer were fatal.
More information is availible at the FDA website.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.